中国生物制药(01177.HK) 公布,集团和博奥信生物技术(南京)就联合开发的TSLP单克隆抗体“BSI-045B (TQC2731)”,与Aclaris Therapeutics, Inc. (ACRS.US) 达成全球合作协议。据介绍,“BSI-045B (TQC2731)”是一款靶向胸腺基质淋巴细胞生成素(TSLP)的人源化单克隆抗体,可以阻止TSLP靶向的免疫细胞释放促炎细胞因子。目前...
Source Link中国生物制药(01177.HK) 公布,集团和博奥信生物技术(南京)就联合开发的TSLP单克隆抗体“BSI-045B (TQC2731)”,与Aclaris Therapeutics, Inc. (ACRS.US) 达成全球合作协议。据介绍,“BSI-045B (TQC2731)”是一款靶向胸腺基质淋巴细胞生成素(TSLP)的人源化单克隆抗体,可以阻止TSLP靶向的免疫细胞释放促炎细胞因子。目前...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.